2020 Revenues ($USD) : $8,796,600,000
2020 R&D spend : $141,800,000
2020 Number of Employees : 27,000
Fiscal Year End : 6/30/2020
Key People : Paul Perreault, CEO

CSL Behring is a biotechnology company developing recombinant and plasma-derived technology for rare and serious diseases such as hemophilia, von Willebrand disease, primary immune deficiencies, chronic inflammatory demyelinating polyneuropathy, hereditary angioedema and inherited respiratory disease. Australia-based CSL's two product portfolios, CSL Behring and Seqirus, provide therapeutics and influenza vaccines to different global populations. –DK